Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle.

Jens Schmidt, Konstanze Barthel, Arne Wrede, Mohammad Salajegheh, Mathias Bähr, Marinos C Dalakas
Author Information
  1. Jens Schmidt: Neuromuscular Diseases Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA. j.schmidt@gmx.org

Abstract

Distinct interrelationships between inflammation and beta-amyloid-associated degeneration, the two major hallmarks of the skeletal muscle pathology in sporadic inclusion body myositis (sIBM), have remained elusive. Expression of markers relevant for these pathomechanisms were analysed in biopsies of sIBM, polymyositis (PM), dermatomyositis (DM), dystrophic and non-myopathic muscle as controls, and cultured human myotubes. By quantitative PCR, a higher upregulation was noted for the mRNA-expression of CXCL-9, CCL-3, CCL-4, IFN-gamma, TNF-alpha and IL-1 beta in sIBM muscle compared to PM, DM and controls. All inflammatory myopathies displayed overexpression of degeneration-associated markers, yet only in sIBM, expression of the mRNA of amyloid precursor protein (APP) significantly and consistently correlated with inflammation in the muscle and mRNA-levels of chemokines and IFN-gamma. Only in sIBM, immunohistochemical analysis revealed that inflammatory mediators including IL-1 beta co-localized to beta-amyloid depositions within myofibres. In human myotubes, exposure to IL-1 beta caused upregulation of APP with subsequent intracellular aggregation of beta-amyloid. Our data suggest that, in sIBM muscle, production of high amounts of pro-inflammatory mediators specifically induces beta-amyloid-associated degeneration. The observations may help to design targeted treatment strategies for chronic inflammatory disorders of the skeletal muscle.

References

  1. Arthritis Rheum. 1997 May;40(5):865-74 [PMID: 9153548]
  2. Am J Pathol. 2006 Jun;168(6):1986-97 [PMID: 16723713]
  3. Brain. 2004 May;127(Pt 5):1182-90 [PMID: 15047591]
  4. Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1314-9 [PMID: 8577761]
  5. Lancet. 2003 Sep 20;362(9388):971-82 [PMID: 14511932]
  6. Clin Exp Immunol. 1998 Sep;113(3):407-14 [PMID: 9737670]
  7. J Neuropathol Exp Neurol. 2000 Feb;59(2):164-9 [PMID: 10749105]
  8. J Biol Chem. 2004 Dec 17;279(51):53524-32 [PMID: 15385569]
  9. Neurology. 2006 Jan 24;66(2 Suppl 1):S39-48 [PMID: 16432144]
  10. FASEB J. 2005 Mar;19(3):362-70 [PMID: 15746179]
  11. Neurology. 2002 Jun 25;58(12):1779-85 [PMID: 12084877]
  12. Nat Clin Pract Neurol. 2006 Aug;2(8):437-47 [PMID: 16932602]
  13. Int Immunol. 2002 Aug;14(8):917-24 [PMID: 12147628]
  14. Ann N Y Acad Sci. 2007 Aug;1109:441-53 [PMID: 17785333]
  15. J Neuropathol Exp Neurol. 1997 May;56(5):479-84 [PMID: 9143260]
  16. Mol Cell Neurosci. 2001 May;17(5):793-810 [PMID: 11358479]
  17. Neuropathol Appl Neurobiol. 2005 Feb;31(1):70-9 [PMID: 15634233]
  18. Brain. 2000 Feb;123 ( Pt 2):374-9 [PMID: 10648444]
  19. Ann N Y Acad Sci. 2000;917:154-64 [PMID: 11268339]
  20. J Neuroimmunol. 2003 Aug;141(1-2):125-31 [PMID: 12965263]
  21. J Biol Chem. 2004 Apr 2;279(14):14456-63 [PMID: 14732706]
  22. Brain. 2005 Aug;128(Pt 8):1887-96 [PMID: 15857930]
  23. J Immunol. 2004 Jun 15;172(12):7713-20 [PMID: 15187154]
  24. Am J Pathol. 1998 Dec;153(6):1687-93 [PMID: 9846958]
  25. Trends Immunol. 2005 Jul;26(7):373-80 [PMID: 15922662]
  26. J Neuropathol Exp Neurol. 1996 Mar;55(3):342-7 [PMID: 8786392]
  27. Ann Neurol. 2007 May;61(5):476-83 [PMID: 17469125]
  28. J Neurosci. 2004 Jul 21;24(29):6457-65 [PMID: 15269255]
  29. Neurology. 2000 Mar 14;54(5):1033-41 [PMID: 10720271]
  30. Neurobiol Aging. 2006 Mar;27(3):423-32 [PMID: 15950323]
  31. Curr Rheumatol Rep. 2007 Aug;9(4):286-90 [PMID: 17688837]
  32. J Neuroimmunol. 2005 Feb;159(1-2):66-74 [PMID: 15652404]
  33. Cardiovasc Res. 2002 Apr;54(1):95-104 [PMID: 12062366]
  34. Clin Immunol. 2000 Feb;94(2):99-104 [PMID: 10637094]
  35. Arch Neurol. 1998 Dec;55(12):1509-12 [PMID: 9865793]
  36. Front Biosci. 2008 Jan 01;13:2548-77 [PMID: 17981734]
  37. Neuromuscul Disord. 1999 Jun;9(4):239-46 [PMID: 10399751]
  38. Biochem Biophys Res Commun. 2003 Aug 8;307(4):922-7 [PMID: 12878199]
  39. Lancet. 2001 Dec 8;358(9297):1962-4 [PMID: 11747923]
  40. Am J Pathol. 1998 Dec;153(6):1679-86 [PMID: 9846957]
  41. Ann Neurol. 2003 Dec;54(6):781-9 [PMID: 14681887]

Grants

  1. /Intramural NIH HHS

MeSH Term

Amyloid beta-Peptides
Amyloid beta-Protein Precursor
Biopsy
Cells, Cultured
Dermatomyositis
Humans
Inflammation Mediators
Interleukin-1beta
Muscle Fibers, Skeletal
Muscle, Skeletal
Myositis, Inclusion Body
Polymyositis
RNA, Messenger
Reverse Transcriptase Polymerase Chain Reaction
Up-Regulation

Chemicals

Amyloid beta-Peptides
Amyloid beta-Protein Precursor
Inflammation Mediators
Interleukin-1beta
RNA, Messenger

Word Cloud

Created with Highcharts 10.0.0musclesIBMIL-1betainflammationskeletalinflammatoryAPPbeta-amyloidbeta-amyloid-associateddegenerationmarkersPMDMcontrolshumanmyotubesupregulationIFN-gammamediatorsinducesDistinctinterrelationshipstwomajorhallmarkspathologysporadicinclusionbodymyositisremainedelusiveExpressionrelevantpathomechanismsanalysedbiopsiespolymyositisdermatomyositisdystrophicnon-myopathicculturedquantitativePCRhighernotedmRNA-expressionCXCL-9CCL-3CCL-4TNF-alphacomparedmyopathiesdisplayedoverexpressiondegeneration-associatedyetexpressionmRNAamyloidprecursorproteinsignificantlyconsistentlycorrelatedmRNA-levelschemokinesimmunohistochemicalanalysisrevealedincludingco-localizeddepositionswithinmyofibresexposurecausedsubsequentintracellularaggregationdatasuggestproductionhighamountspro-inflammatoryspecificallyobservationsmayhelpdesigntargetedtreatmentstrategieschronicdisordersInterrelationsIBM:accumulation

Similar Articles

Cited By